MetaCap

BioNTech SE ADR (BNTX)

NASDAQ: BNTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

80.96-0.42 (-0.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BNTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$20.07B
EPS (TTM)
-$6.83
Ex-dividend date
Jun 2, 2022
52-week range
79.52 – 124.00
Day range
80.27 – 82.87
Volume / Avg
1.71M / 1.08M
Beta
—

52-week range

$79.52$124.00

BNTX stock today

Shares of BioNTech (BNTX) finished lower on Nov 20 at $80.96, a drop of 0.52% or $0.42 per share, versus the S&P 500's 3.70% decline. At this level, BNTX sits near the bottom of its 52-week range of $79.52 to $124.00: 34.7% below the high, set on Jan 22, 2026 and 1.8% above the low. BNTX is down 15.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 15.3%.

BioNTech has posted a net loss over the last twelve months (EPS of -$6.83), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About BioNTech

Company profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Ugur Sahin M.D.
Headquarters
Mainz
Employees
7,807
IPO year
2019

Analyst forecast

Forecast

Consensus (21 analysts)

buy

Avg. price target

$112.14+38.51%

  • Strong buy 1
  • Buy 13
  • Hold 7
  • Sell 0
  • Strong sell 0

Target range

Low $74.32High $143.69

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.14 vs $0.85
Surprise
-116.47%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$2.11
Ex-dividend date
Jun 2, 2022

BNTX news

All BNTX news

BioNTech peers

Health Care sector
BNTX peer companies
CompanyPrice% ChgMarket capCompare
EXELExelixis Inc.64.63-1.82%$15.77Bvs BNTX
NBIXNeurocrine Biosciences Inc.150.57-3.84%$15.24Bvs BNTX
TECHBio-Techne Corp72.67-0.04%$11.42Bvs BNTX
RGENRepligen Corporation163.81-3.81%$10.47Bvs BNTX
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs BNTX
QGENQiagen N.V.49.30-0.66%$10.18Bvs BNTX
KYMRKymera Therapeutics Inc.115.31-3.42%$9.84Bvs BNTX
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs BNTX

Indexes, lists and sector

BioNTech stock FAQ

What is BioNTech's stock price today?

BNTX last traded at $80.96 as of Nov 20, 4:00 PM EST, down 0.52% on the day. Prices are delayed at least 15 minutes.

Does BioNTech pay a dividend?

Yes. BioNTech pays $0.00 per share annually. The most recent dividend of $2.11 had an ex-dividend date of Jun 2, 2022.

Who is BioNTech's CEO?

Dr. Ugur Sahin M.D. is the chief executive officer of BioNTech SE ADR, which has about 7,807 employees.

What is the BNTX 52-week high?

The 52-week high for BNTX is $124.00 and the 52-week low is $79.52. The stock is currently 34.7% below its high.

Compare BNTX